Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication for financial results for the quarter ended June 30, 2025
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma Limited (formerly Stelis Biopharma) has published its unaudited financial results for the quarter ended June 30, 2025 in the Financial Express and Lokmat newspapers on August 6, 2025, as mandated by SEBI's listing regulations. On a consolidated basis, revenue from operations surged to Rs. 82.73 crore in Q1 FY26, nearly four times the Rs. 20.23 crore reported in the same quarter last year. Despite the strong top-line growth, the company posted a marginal consolidated net loss of Rs. 1.86 lakh after tax, compared to a loss of Rs. 6.54 crore in Q1 FY25. On a standalone basis, the company swung to a net profit of Rs. 2.48 crore from a loss of Rs. 2.40 crore in the year-ago quarter, with standalone revenue rising to Rs. 32.10 crore from Rs. 24.00 crore.
This is a routine compliance filing republishing results that were already disclosed to the exchanges, so no new information is being shared with the market. The strong revenue growth on a consolidated basis is a positive signal, but the company remains inconsistent on profitability, so the stock is unlikely to see a meaningful reaction from this filing alone.